Non-Small Cell Lung Cancer: New Preclinical Data

Non-Small Cell Lung Cancer: New Preclinical Data

Results suggest that mesothelin-targeted TriKE can work alongside current standard of care and provide benefit even in the hypoxic environment of a solid tumor. GT Biopharma, Inc., a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, presented preclinical data demonstrating its novel TriKE driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment at ESMO’s Targeted Anticancer […]

Click here to read: eTurboNews | TravelWireNews | TravelNewsOnline

Click here to read the full article.

Non-Small Cell Lung Cancer: New Preclinical Data

 

Source: eTurboNews

Related posts